Cue Biopharma (CUE) Income from Continuing Operations (2017 - 2025)

Cue Biopharma has disclosed Income from Continuing Operations across 9 years of filings, most recently posting 23207000.0 for Q4 2025.

• Income from Continuing Operations for Q4 2025 came in at 23207000.0, down 1.73% year-over-year; the trailing twelve-month figure through Dec 2025 was 4732000.0 (up 31.6% YoY), and the FY2025 annual result was 5174000.0, up 25.22% from the prior year.
• Income from Continuing Operations came in at 23207000.0 for Q4 2025 at Cue Biopharma, up from 7373000.0 in the prior quarter.
• In the past five years, Income from Continuing Operations ranged from a high of 23616000.0 in Q4 2024 to a low of 14255000.0 in Q1 2022.
• The 5-year median for Income from Continuing Operations is 11530500.0 (2022), against an average of 7865308.75.
• Across the five-year window, Income from Continuing Operations plunged 80.42% in 2022 and soared 282.69% in 2024, its largest moves.
• Cue Biopharma's Income from Continuing Operations stood at 7889175.0 in 2021, then slumped by 80.42% to 14234000.0 in 2022, then grew by 9.18% to 12927000.0 in 2023, then jumped by 282.69% to 23616000.0 in 2024, then fell by 1.73% to 23207000.0 in 2025.
• The last three Income from Continuing Operations figures came in at 23207000.0 (Q4 2025), 7373000.0 (Q3 2025), and 8437000.0 (Q2 2025), per Business Quant data.